651. Auto-immune anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis: three case reports.
- Author
-
Bashiri FA, Al-Rasheed AA, Hassan SM, Hamad MHA, El Khashab HY, Kentab AY, AlBadr FB, and Salih MA
- Subjects
- Adrenal Cortex Hormones therapeutic use, Anti-N-Methyl-D-Aspartate Receptor Encephalitis drug therapy, Child, Child, Preschool, Diagnosis, Differential, Female, Humans, Immunoglobulins, Intravenous therapeutic use, Immunologic Factors therapeutic use, Infant, Magnetic Resonance Imaging, Rituximab therapeutic use, Treatment Outcome, Anti-N-Methyl-D-Aspartate Receptor Encephalitis diagnosis, Anti-N-Methyl-D-Aspartate Receptor Encephalitis pathology, Autoantibodies blood, Brain diagnostic imaging, Receptors, N-Methyl-D-Aspartate immunology
- Abstract
Anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis is a recently identified auto-immune disorder characterised by severe memory deficit, a decreased level of consciousness, seizures, autonomic dysfunction and movement disorders. Three girls with the disorder are reported; they were aged 4 years, 5 years and 10 months. The 10-month-old infant who is one of the youngest patients reported with anti-NMDAR encephalitis worldwide, had MRI features suggestive of herpes simplex encephalitis (known to trigger anti-NMDAR encephalitis), but CSF PCR for herpes simplex was negative. All the patients presented with seizures, behavioural change, regression of speech, dystonia and choreo-athetosis. Anti-NMDAR antibodies were detected in all patients' sera and cerebrospinal fluid (CSF). Intravenous immunoglobulin, corticosteroids and rituximab were administered at different intervals. Cases 1 and 2 made a full recovery, but case 3 has mild motor and speech delay. Patients who present with encephalopathy, seizures and movement disorders should be tested for anti-NMDAR antibodies in serum and CSF in addition to being screened for herpes simplex encephalitis.
- Published
- 2017
- Full Text
- View/download PDF